Business Wire

Bluehole Publishes an Industry Comment on Vuse Overtaking Juul and Becoming the U.S Vaping Market Champion Again

12.5.2022 12:47:00 EEST | Business Wire | Press release

Share

China’s leading vaping media, Bluehole New Consumption, today publishes an industry comment on Vuse overtaking Juul and becoming the U.S vaping market champion again.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220512005478/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

Here below is the full article:

According to Nielsen, for the two weeks ended April 9, 2022, Vuse has surpassed Juul and become No.1 in U.S. e-cigarette sales with a market share of 35 percent, driven by the sale of its flagship product Vuse Alto, which represented over 90% of Vuse revenues in the U.S. in 2021. Being back on top in the U.S market has strengthened Vuse's global leadership.

It is another milestone for Vuse to be the U.S top-selling vaping brand again, since Juul overtook it in 2017. Juul, the emerging brand founded in 2015, had already captured a massive 68% share of the US vaping market within 3 years while Vuse's market share had reduced to 10% from 44.2% in 2016.

In order to turn the tide in the competition against Juul, Vuse had started searching for a new manufacturer and atomization technology provider on a global scale, and considered introducing a game-changing product. In 2018, Vuse entered into partnership with FEELM, the flagship atomization tech brand belonging to SMOORE and soon launched Vuse Alto in August.

In contract to Juul, which mounts traditional cotton coil, Vuse Alto provides a revolutionary vaping experience by adopting FEELM ceramic coil, and Vuse also started swinging momentum in its favor. Since 2019, Vuse's US market share has rocketed, with Vuse Alto becoming one of the most popular vaping products worldwide. In 2021, Vuse announced to be No.1 global vaping brand and reached a full year value share of 33.5% in the top five vapor markets (the U.S, Canada, France, Germany and the UK), which account for approximately 75% of total industry vapor revenue (closed-system). In the US market, Vuse’s US value share reached 35.9% in December 2021. It has managed to close 27% value share point gap in just 2 years, with only 0.1% difference with Juul (36%).

Equipped with an industry-leading ceramic coil, Vuse Alto brings a consistently smooth vaping experience and boasts a long-lasting pod with extraordinary leakage-proof performance. Moreover, due to the authentic flavor reproduction of FEELM ceramic coil, Vuse Alto features a full-bodied, rich taste of tobacco and menthol. It becomes an increasingly prominent competitive edge, especially after the U.S FDA banned e-cigarettes with flavors other than tobacco and menthol in February 2020, to address youth vaping epidemic. Meanwhile, Juul has been stuck in youth marketing controversy and faced mounting state lawsuits in the US.

In October 2021, the FDA has issued first marketing granted orders to Vuse (Solo), recognizing the public health benefits of Vuse products, particularly for addicted adult smokers seeking for switchover. Later in April 2022, the FDA has approved NJOY Ace for sale. This latest approved product is also powered by FEELM atomization technology, thereby reaffirming the harm reduction potential of this ceramic coil. Moreover, Vuse Alto shares the same FEELM atomization technology with NJOY Ace.

To read the original article, please visit: https://bluehole.com.cn/news/detail/49834

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Chen Bianji
(86)13530848319

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f

Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 15:00:00 EET | Press release

Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end workflows spanning onboarding, KYC, AML, fraud, underwriting, payments, disputes, servicing, and collections. For

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye